Key facts
- This page summarizes Stanley C. Erck's Form 4 filing for MAXCYTE, INC. (MXCT).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Nov 2024, 16:25.
Stanley C. Erck - 01 Nov 2024 Form 4 Insider Report for MAXCYTE, INC. (MXCT)
- Reporting relationship
- Director
- Issuer ticker
- MXCT
- Reported as of
- 01 Nov 2024
- Net transaction value
- -$175,496
- SEC form
- 4
- Accepted by SEC
- 05 Nov 2024, 16:25:05 UTC
- Prior SEC filing
- 02 Oct 2024
- Next SEC filing
- 23 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Leaf, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stanley C. Erck filed Form 4 for MAXCYTE, INC. (MXCT) on 05 Nov 2024.
Change
- Previous filing in this sequence was filed on 02 Oct 2024.
- Current net transaction value: -$175,496.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MXCT
transaction
Common Stock
Options Exercise
- Transaction value
- $1,908
- Shares
- +47,689
- Change %
- +18%
- Price
- $0.0400
- Shares after
- 316,807
- Date
- 01 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
MXCT
transaction
Common Stock
Sale
- Transaction value
- $177,403
- Shares
- -47,689
- Change %
- -15%
- Price
- $3.72
- Shares after
- 269,118
- Date
- 01 Nov 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MXCT
transaction
Derivative
Employee Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -47,689
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 01 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 47,689
- Exercise price
- $0.0400
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2024. The option that is the subject of the trading plan is scheduled to expire by its terms on November 11, 2024.
Footnote F2
The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.61 to $3.755, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
This option is fully vested and exercisable.